“Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026” Report Highlights: • Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 • Role of FGFR Inhibitors in Cancer Therapy • Global FGFR Market Assessment (US$) by Region & Cancer Type • Clinical & Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre & Truseltiq) • Dosage & Drug Price Insight on Approved FGFR Inhibitors • Comprehensive Clinical Trials Insight by Company, Country, Phase & Patient Segment: 53 Drugs in Trials
Recent breakthrough with respect to small molecule based therapy in the oncology segment has set up remarkable achievements in terms of improving the cancer survival rate. The FGFR inhibitors are considered as one of advanced anticancer therapy, which belongs to the class of receptor kinase inhibiting small molecules and now widely accepted for the treatment of various cancer types including bladder cancer, breast cancer, lung cancer gastric cancer, lymphoma, myeloma etc. In a short period of time, FGFR inhibitors has made its way through all the challenges and led to a stage where the availability of the therapy is highly appreciated and praised.
The mutation or over expression of FGFR makes them ideal target for management of cancer and most of the researchers exploring the therapeutic potential of this class concluded the beneficial effects of this approach. Further, the FGFR alterations are also observed in rare cancers and hence this approach has potential to play a crucial role in the management of untreatable rare types of cancers. Currently, the market of FGFR inhibitors is at nascent stage, which is driven by the sales of 3 approved products of this class i.e. Balversa, Pemazyre and Truseltiq. Balversa is recommended for management of bladder cancer while Pemazyre and Truseltiq are recommended for the management of rare cancer termed as Cholangiocarcinoma. Many new drugs of this class are also believed to get orphan designation in upcoming years, which further boost the market size of this segment.
Balversa is expected to lead the market segment as its sales value is believed to increase exponentially after its approval in the leading regions including Europe and Japan. The estimated market size of FGFR inhibitor is about US$ 100 Million in year 2020 and it is believed to grow with CAGR of more than 80% during the next 6 years as most of the market related factors are indicating towards the increasing acceptance of this segment in near future. Further, US will lead FGFR market due to availability of huge cancer burden and leading pharmaceutical companies. The drug approval process is now simplified in US due to availability of all the three drugs of this class and hence most of the new FGFR inhibitors will first get approval in this region.
With an aim of improving the market penetrability and commercialization of FGFR inhibitors, the leading pharmaceutical companies are expected to collaborate with CROs and regional pharmaceutical companies of developing companies, which will increase the market size of this novel segment in regions such as Asia-Pacific, Middle-East and Latin America. The leading pharmaceutical companies working in this sector are Amgen, Astem pharma, AstraZenca, Bayer, BMS, Incyte, Roche, Taiho, Janssen pharmaceuticals, Novartis etc. while many other companies are working on FGFR inhibitors in preclinical studies.
“Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026” report involves in depth analysis of the various parameters related to this segment along with the analysis of current as well as future market opportunity. The report also analyzes the wide range of applications of this class in cancer management along with the clinical trends, market drivers, and possible challenges related to FGFR inhibitors market. Further, multiple parameters are considered to forecast and analyze the global, regional and indication based market size for FGR inhibitors drugs.
Our reports have been used by over 10K customers, including:
Report Scope: This report aims to provide a comprehensive study of the global market for oncology pharmaceuticals (cancer drugs).It provides a detailed description of the different oncology pharmaceutical types (targeted therapy, immunotherapy, chemotherapy and hormone therapy) and current and historical market revenues. The...
Retinoic Acid Receptor Alpha - Drugs In Development, 2021 Summary Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) pipeline Target constitutes close to 15 molecules. The latest report Retinoic Acid Receptor Alpha - Drugs In Development, 2021,...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the pharmaceutical contract development and manufacturing organization (CMO) market are Recipharm AB, Pfizer Inc., Boehringer Ingelheim International GmbH., Aenova Group, Famar, Jubilant Life Sciences Limited, Catalent Pharma Solutions, Chemicals Limited, Dishman Pharmaceuticals and HAUPT Pharma AG. The global pharmaceutical...
Pharmaceutical Refrigerators and Freezers market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Pharmaceutical Refrigerators and Freezers Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Pharmaceutical Refrigerators...
Global Pharmaceutical Partnering Terms and Agreements 2017 to 2021 report provides a detailed understanding and analysis of how and why companies enter Pharmaceutical partnering deals. This report provides details of the latest Pharmaceutical agreements announced in the life sciences since 2017. The report takes...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., New England Biolabs and Promega Corporation. The global protein expression market is expected to grow from $2.01 billion in 2020 to $2.13 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth...
The global alzheimer’s drugs market reached a value of US$ 6.34 Billion in 2020. Looking forward, the analyst expects the market to grow at a CAGR of 6.50% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights...
Forecasts by Type (Modular Manufacturing, Data-Driven Manufacturing, Others), End-user (Pharma Companies, CMOs) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Flexible Manufacturing Companies AND COVID-19 Recovery Scenarios Increased Focus on Reducing Manufacturing Costs The pharmaceutical...
Melanocyte Stimulating Hormone Receptor - Drugs In Development, 2021 Summary Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds...
Real-world data and real-world evidence are used to monitor the post-market safety and adverse events of drugs.The monitoring of this data assists in making regulatory decisions. The healthcare community is using RWE and RWD to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice. The...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.